These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27533468)

  • 1. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
    Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
    Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
    Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
    Vu HL; Aplin AE
    Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
    Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
    Kiessling MK; Curioni-Fontecedro A; Samaras P; Lang S; Scharl M; Aguzzi A; Oldrige DA; Maris JM; Rogler G
    PLoS One; 2016; 11(1):e0147682. PubMed ID: 26821351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
    Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
    Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
    Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
    Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
    Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
    Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
    Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
    Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.
    Parris JLD; Barnoud T; Leu JI; Leung JC; Ma W; Kirven NA; Poli ANR; Kossenkov AV; Liu Q; Salvino JM; George DL; Weeraratna AT; Chen Q; Murphy ME
    Cancer Res Commun; 2021 Oct; 1(1):17-29. PubMed ID: 35187538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
    J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
    Hong A; Piva M; Liu S; Hugo W; Lomeli SH; Zoete V; Randolph CE; Yang Z; Wang Y; Lee JJ; Lo SJ; Sun L; Vega-Crespo A; Garcia AJ; Shackelford DB; Dubinett SM; Scumpia PO; Byrum SD; Tackett AJ; Donahue TR; Michielin O; Holmen SL; Ribas A; Moriceau G; Lo RS
    Cancer Discov; 2021 Mar; 11(3):714-735. PubMed ID: 33318037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
    Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
    Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
    Nguyen MQ; Teh JLF; Purwin TJ; Chervoneva I; Davies MA; Nathanson KL; Cheng PF; Levesque MP; Dummer R; Aplin AE
    J Invest Dermatol; 2020 Nov; 140(11):2242-2252.e7. PubMed ID: 32389536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
    Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.